Citadel Advisors’s Ayala Pharmaceuticals, Inc. Common Stock AYLA Stock Holding History

Citadel Advisors’s Portfolio AYLA Stock Details AYLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-11,415	Closed	-$4.8K	–	16182
2022 Q4	$4.8K	Buy	+11,415	New	+$7.41K	﹤0.01%	14063
2022 Q3	–	Sell	-135,502	Closed	-$148K	–	14082
2022 Q2	$148K	Buy	+135,502	New	+$310K	﹤0.01%	11002
2021 Q3	–	Sell	-10,457	Closed	-$107K	–	15032
2021 Q2	$107K	Buy	+10,457	New	+$107K	﹤0.01%	12866

Citadel Advisors's AYLA Position: Q1 2023 in Review

Citadel Advisors sold out of Ayala Pharmaceuticals, Inc. Common Stock (AYLA) in Q1 2023, closing a stake of 11,415 shares — an estimated $4.8K sold.

Citadel Advisors first reported a position in AYLA in Q2 2021 and held it in 3 quarters. The position peaked at $148K in Q2 2022. 0 funds tracked by Wall St. Rank hold AYLA as of Q1 2023.

Citadel Advisors reported no remaining Ayala Pharmaceuticals, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Citadel Advisors sold 11,415 Ayala Pharmaceuticals, Inc. Common Stock shares in Q1 2023, an estimated $4.8K.
Citadel Advisors first reported a position in Ayala Pharmaceuticals, Inc. Common Stock in Q2 2021 and held it in 3 quarters.
Citadel Advisors's Ayala Pharmaceuticals, Inc. Common Stock position peaked at $148K in Q2 2022.
0 funds tracked by Wall St. Rank held Ayala Pharmaceuticals, Inc. Common Stock as of Q1 2023.

Based on Citadel Advisors's 13F filing for Q1 2023, filed 15 May 2023.